1. Home
  2. NRDS vs PCRX Comparison

NRDS vs PCRX Comparison

Compare NRDS & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NerdWallet Inc.

NRDS

NerdWallet Inc.

HOLD

Current Price

$10.65

Market Cap

1.0B

Sector

Technology

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$23.25

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NRDS
PCRX
Founded
2009
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
NRDS
PCRX
Price
$10.65
$23.25
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$14.33
$37.20
AVG Volume (30 Days)
829.9K
573.7K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
68.42
107.44
EPS
0.64
0.16
Revenue
$836,600,000.00
$541,533,000.00
Revenue This Year
$10.13
$6.78
Revenue Next Year
$7.11
$8.54
P/E Ratio
$16.39
$140.69
Revenue Growth
21.67
26.04
52 Week Low
$7.86
$18.80
52 Week High
$16.24
$27.99

Technical Indicators

Market Signals
Indicator
NRDS
PCRX
Relative Strength Index (RSI) 53.19 54.40
Support Level $10.23 $22.57
Resistance Level $10.70 $23.94
Average True Range (ATR) 0.36 0.77
MACD 0.08 -0.03
Stochastic Oscillator 71.30 61.42

Price Performance

Historical Comparison
NRDS
PCRX

About NRDS NerdWallet Inc.

Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: